 | • レポートコード：MRC2304A064 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、241ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の当調査レポートでは、2021年に596.2億ドルであった世界の体外診断（IVD）市場規模が2022年に633.4億ドルへと拡大、更に2027年までにCAGR 6.40％で成長して865.4億ドルに達すると予測しています。当書は、体外診断（IVD）の世界市場を総合的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、コンポーネント別分析（データ管理ソフトウェア、器具、試薬＆キット、サービス）、技術別分析（臨床化学、凝固＆止血、血液、免疫化学、微生物）、エンドユーザー別分析（病院＆医療提供者、研究所、患者自己検査）、用途別分析（自己免疫疾患、心臓病、糖尿病、薬物検査、HIV/エイズ）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの構成でまとめています。なお、当書には、Biomérieux Sa、Danaher Corporation、Diasorin、Johnson & Johnson、Ortho Clinical Diagnostics、Qiagen、Roche Diagnostics、Siemens AG、Sysmex Corporation、Thermo Fisher Scientificなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の体外診断（IVD）市場規模：コンポーネント別 - データ管理ソフトウェアの市場規模 - 器具の市場規模 - 試薬＆キットの市場規模 - サービスの市場規模 ・世界の体外診断（IVD）市場規模：技術別 - 臨床化学の市場規模 - 凝固＆止血の市場規模 - 血液の市場規模 - 免疫化学の市場規模 - 微生物の市場規模 ・世界の体外診断（IVD）市場規模：エンドユーザー別 - 病院＆医療提供者における市場規模 - 研究所における市場規模 - 患者自己検査における市場規模 ・世界の体外診断（IVD）市場規模：用途別 - 自己免疫疾患における市場規模 - 心臓病における市場規模 - 糖尿病における市場規模 - 薬物検査における市場規模 - HIV/エイズにおける市場規模 ・世界の体外診断（IVD）市場規模：地域別 - 南北アメリカの体外診断（IVD）市場規模 アメリカの体外診断（IVD）市場規模 カナダの体外診断（IVD）市場規模 ブラジルの体外診断（IVD）市場規模 ... - アジア太平洋の体外診断（IVD）市場規模 日本の体外診断（IVD）市場規模 中国の体外診断（IVD）市場規模 インドの体外診断（IVD）市場規模 韓国の体外診断（IVD）市場規模 台湾の体外診断（IVD）市場規模 ... - ヨーロッパ/中東/アフリカの体外診断（IVD）市場規模 イギリスの体外診断（IVD）市場規模 ドイツの体外診断（IVD）市場規模 フランスの体外診断（IVD）市場規模 ロシアの体外診断（IVD）市場規模 ... - その他地域の体外診断（IVD）市場規模 ・競争状況 ・企業情報 |
The Global In-Vitro Diagnostics Market size was estimated at USD 59.62 billion in 2021 and expected to reach USD 63.34 billion in 2022, and is projected to grow at a CAGR 6.40% to reach USD 86.54 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the In-Vitro Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Component, the market was studied across Data Management Software, Instruments, Reagents & Kits, and Services.
Based on Technology, the market was studied across Clinical Chemistry, Coagulation & Hemostasis, Hematology, Immunochemistry, Microbiology, Molecular Diagnostics, and Urinalysis. The Clinical Chemistry is further studied across Basic Metabolic Panel, Electrolyte Panel, Lipid Profile, Liver Panel, Renal Profile, Specialty Chemical Tests, and Thyroid Function Panel. The Immunochemistry is further studied across Enzyme-Linked Immunosorbent Assay, Enzyme-Linked Immunospot Assays, Radioimmunoassay, Rapid Test, and Western Blotting. The Enzyme-Linked Immunosorbent Assay is further studied across Chemiluminescence Immunoassays, Colorimetric Immunoassays, and Fluorescence Immunoassays. The Molecular Diagnostics is further studied across DNA Sequencing & Next-Generation Sequencing, Hybridization, Isothermal Nucleic Acid Amplification Technology, Microarray, and Polymerase Chain Reaction.
Based on End User, the market was studied across Hospitals & Care Providers, Laboratories, and Patient Self-Testing.
Based on Application, the market was studied across Autoimmune Diseases, Cardiology, Diabetes, Drug Testing, HIV/Aids, Infectious Diseases, Nephrology, and Oncology.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for In-Vitro Diagnostics market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the In-Vitro Diagnostics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global In-Vitro Diagnostics Market, including Biomérieux Sa, Danaher Corporation, Diasorin, Johnson & Johnson, Ortho Clinical Diagnostics, Qiagen, Roche Diagnostics, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global In-Vitro Diagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global In-Vitro Diagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global In-Vitro Diagnostics Market?
4. What is the competitive strategic window for opportunities in the Global In-Vitro Diagnostics Market?
5. What are the technology trends and regulatory frameworks in the Global In-Vitro Diagnostics Market?
6. What is the market share of the leading vendors in the Global In-Vitro Diagnostics Market?
7. What modes and strategic moves are considered suitable for entering the Global In-Vitro Diagnostics Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Geriatric population and prevalence of chronic and infectious diseases in Americas
5.1.1.2. Growing awareness on self-testing and personalized medicine
5.1.1.3. Increasing adoption automated instruments and equipment in laboratories
5.1.1.4. Increasing deployment of Point-of-Care testing facilities
5.1.2. Restraints
5.1.2.1. Unfavorable reimbursement
5.1.3. Opportunities
5.1.3.1. Development of condition-specific markers and tests
5.1.3.2. Attractive companion diagnostics
5.1.3.3. Growth opportunities in emerging countries
5.1.4. Challenges
5.1.4.1. Changing the regulatory landscape
5.1.4.2. Operational limitations faced in conducting diagnostic tests
5.2. Cumulative Impact of COVID-19
6. In-Vitro Diagnostics Market, by Component
6.1. Introduction
6.2. Data Management Software
6.3. Instruments
6.4. Reagents & Kits
6.5. Services
7. In-Vitro Diagnostics Market, by Technology
7.1. Introduction
7.2. Clinical Chemistry
7.3.1. Basic Metabolic Panel
7.3.2. Electrolyte Panel
7.3.3. Lipid Profile
7.3.4. Liver Panel
7.3.5. Renal Profile
7.3.6. Specialty Chemical Tests
7.3.7. Thyroid Function Panel
7.3. Coagulation & Hemostasis
7.4. Hematology
7.5. Immunochemistry
7.6.1. Enzyme-Linked Immunosorbent Assay
7.6.2.1. Chemiluminescence Immunoassays
7.6.2.2. Colorimetric Immunoassays
7.6.2.3. Fluorescence Immunoassays
7.6.2. Enzyme-Linked Immunospot Assays
7.6.3. Radioimmunoassay
7.6.4. Rapid Test
7.6.5. Western Blotting
7.6. Microbiology
7.7. Molecular Diagnostics
7.8.1. DNA Sequencing & Next-Generation Sequencing
7.8.2. Hybridization
7.8.3. Isothermal Nucleic Acid Amplification Technology
7.8.4. Microarray
7.8.5. Polymerase Chain Reaction
7.8. Urinalysis
8. In-Vitro Diagnostics Market, by End User
8.1. Introduction
8.2. Hospitals & Care Providers
8.3. Laboratories
8.4. Patient Self-Testing
9. In-Vitro Diagnostics Market, by Application
9.1. Introduction
9.2. Autoimmune Diseases
9.3. Cardiology
9.4. Diabetes
9.5. Drug Testing
9.6. HIV/Aids
9.7. Infectious Diseases
9.8. Nephrology
9.9. Oncology
10. Americas In-Vitro Diagnostics Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific In-Vitro Diagnostics Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa In-Vitro Diagnostics Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Biomérieux Sa
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Danaher Corporation
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Diasorin
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Johnson & Johnson
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Ortho Clinical Diagnostics
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Qiagen
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Roche Diagnostics
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Siemens AG
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Sysmex Corporation
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Thermo Fisher Scientific
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing